vers la météo de la validation par utilisateur

Ingenuity262

precedent - 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 - suivant

Phrase 66 - PMID ?

In lymphocytes from __SP__ , oral administration of __NODE__ ( with a dosage of 600 mg/day and a treatment period of 7 days ) is involved in expression of __SP__ __NODE__ mRNA .


Non annotée
Je ne sais pas
Je n'ai pas trouvé d'analyse satisfaisante


Commentaires :
Analyse 0 
         +------------------------------------------------------COMP:V_PASS-N(In)-----------------------------------------------------+                                           
         |                                +---------------------------------------SUBJ:V_PASS-N---------------------------------------+                                           
         |                                |              +------------------------APPOS------------------------+                      |            +-------COMP:N-N(of)-------+   
         |                                |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+           |            |           +-MOD_ATT:N-ADJ+   
         +COMP:N-N(from)+       +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+           +COMP:V_PASS-+           |       +MOD_AT+   
         |              |       |         |              |        |       |       |     |             |        |      |   |           |            |           |       |      |   
 In lymphocytes from __SP__ , oral administration of __NODE__ ( with a dosage of 600 mg/day and a treatment period of 7 days ) is involved in expression of __SP__ __NODE__ mRNA .
COMP:N-N(from) (lymphocyte,__SP__)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,day)
MOD_ATT:N-ADJ (day,7)
COMP:V_PASS-N(In) (involve,lymphocyte)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
Analyse 1 
         +------------------------------------------------------COMP:V_PASS-N(In)-----------------------------------------------------+                                           
         |                                +---------------------------------------SUBJ:V_PASS-N---------------------------------------+                                           
         |                                |              +------------------------APPOS------------------------+                      |            +-------COMP:N-N(of)-------+   
         |                                |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+           |            |           +-MOD_ATT:N-ADJ+   
         +COMP:N-N(from)+       +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+           +COMP:V_PASS-+           |       +MOD_AT+   
         |              |       |         |              |        |       |       |     |             |        |      |   |           |            |           |       |      |   
 In lymphocytes from __SP__ , oral administration of __NODE__ ( with a dosage of 600 mg/day and a treatment period of 7 days ) is involved in expression of __SP__ __NODE__ mRNA .
COMP:N-N(from) (lymphocyte,__SP__)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,day)
MOD_ATT:N-ADJ (day,7)
COMP:V_PASS-N(In) (involve,lymphocyte)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
Analyse 2 
         +------------------------------------------------------COMP:V_PASS-N(In)-----------------------------------------------------+                                           
         |              +---------------------------------------------COMP:V_PASS-N(from)---------------------------------------------+                                           
         |              |                 +---------------------------------------SUBJ:V_PASS-N---------------------------------------+                                           
         |              |                 |              +------------------------APPOS------------------------+                      |            +-------COMP:N-N(of)-------+   
         |              |                 |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+           |            |           +-MOD_ATT:N-ADJ+   
         |              |       +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+           +COMP:V_PASS-+           |       +MOD_AT+   
         |              |       |         |              |        |       |       |     |             |        |      |   |           |            |           |       |      |   
 In lymphocytes from __SP__ , oral administration of __NODE__ ( with a dosage of 600 mg/day and a treatment period of 7 days ) is involved in expression of __SP__ __NODE__ mRNA .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,day)
MOD_ATT:N-ADJ (day,7)
COMP:V_PASS-N(In) (involve,lymphocyte)
COMP:V_PASS-N(from) (involve,__SP__)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
Analyse 3 
         +------------------------------------------------------COMP:V_PASS-N(In)-----------------------------------------------------+                                           
         |              +---------------------------------------------COMP:V_PASS-N(from)---------------------------------------------+                                           
         |              |                 +---------------------------------------SUBJ:V_PASS-N---------------------------------------+                                           
         |              |                 |              +------------------------APPOS------------------------+                      |            +-------COMP:N-N(of)-------+   
         |              |                 |              |        +-------OBJ:V-N-------+                      +COMP:N-N(o+           |            |           +-MOD_ATT:N-ADJ+   
         |              |       +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+           +COMP:V_PASS-+           |       +MOD_AT+   
         |              |       |         |              |        |       |       |     |             |        |      |   |           |            |           |       |      |   
 In lymphocytes from __SP__ , oral administration of __NODE__ ( with a dosage of 600 mg/day and a treatment period of 7 days ) is involved in expression of __SP__ __NODE__ mRNA .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (__NODE__,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,day)
MOD_ATT:N-ADJ (day,7)
COMP:V_PASS-N(In) (involve,lymphocyte)
COMP:V_PASS-N(from) (involve,__SP__)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
Analyse 4 
         +------------------------------------------------------COMP:V_PASS-N(In)-----------------------------------------------------+                                           
         |                                +---------------------------------------SUBJ:V_PASS-N---------------------------------------+                                           
         |                                +--------------------------------APPOS-------------------------------+                      |            +-------COMP:N-N(of)-------+   
         |                                |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+           |            |           +-MOD_ATT:N-ADJ+   
         +COMP:N-N(from)+       +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+           +COMP:V_PASS-+           |       +MOD_AT+   
         |              |       |         |              |        |       |       |     |             |        |      |   |           |            |           |       |      |   
 In lymphocytes from __SP__ , oral administration of __NODE__ ( with a dosage of 600 mg/day and a treatment period of 7 days ) is involved in expression of __SP__ __NODE__ mRNA .
COMP:N-N(from) (lymphocyte,__SP__)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,day)
MOD_ATT:N-ADJ (day,7)
COMP:V_PASS-N(In) (involve,lymphocyte)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
Analyse 5 
         +------------------------------------------------------COMP:V_PASS-N(In)-----------------------------------------------------+                                           
         |                                +---------------------------------------SUBJ:V_PASS-N---------------------------------------+                                           
         |                                +--------------------------------APPOS-------------------------------+                      |            +-------COMP:N-N(of)-------+   
         |                                |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+           |            |           +-MOD_ATT:N-ADJ+   
         +COMP:N-N(from)+       +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+           +COMP:V_PASS-+           |       +MOD_AT+   
         |              |       |         |              |        |       |       |     |             |        |      |   |           |            |           |       |      |   
 In lymphocytes from __SP__ , oral administration of __NODE__ ( with a dosage of 600 mg/day and a treatment period of 7 days ) is involved in expression of __SP__ __NODE__ mRNA .
COMP:N-N(from) (lymphocyte,__SP__)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,day)
MOD_ATT:N-ADJ (day,7)
COMP:V_PASS-N(In) (involve,lymphocyte)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
Analyse 6 
         +------------------------------------------------------COMP:V_PASS-N(In)-----------------------------------------------------+                                           
         |              +---------------------------------------------COMP:V_PASS-N(from)---------------------------------------------+                                           
         |              |                 +---------------------------------------SUBJ:V_PASS-N---------------------------------------+                                           
         |              |                 +--------------------------------APPOS-------------------------------+                      |            +-------COMP:N-N(of)-------+   
         |              |                 |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+           |            |           +-MOD_ATT:N-ADJ+   
         |              |       +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+           +COMP:V_PASS-+           |       +MOD_AT+   
         |              |       |         |              |        |       |       |     |             |        |      |   |           |            |           |       |      |   
 In lymphocytes from __SP__ , oral administration of __NODE__ ( with a dosage of 600 mg/day and a treatment period of 7 days ) is involved in expression of __SP__ __NODE__ mRNA .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,day)
MOD_ATT:N-ADJ (day,7)
COMP:V_PASS-N(In) (involve,lymphocyte)
COMP:V_PASS-N(from) (involve,__SP__)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
Analyse 7 
         +------------------------------------------------------COMP:V_PASS-N(In)-----------------------------------------------------+                                           
         |              +---------------------------------------------COMP:V_PASS-N(from)---------------------------------------------+                                           
         |              |                 +---------------------------------------SUBJ:V_PASS-N---------------------------------------+                                           
         |              |                 +--------------------------------APPOS-------------------------------+                      |            +-------COMP:N-N(of)-------+   
         |              |                 |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+           |            |           +-MOD_ATT:N-ADJ+   
         |              |       +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+           +COMP:V_PASS-+           |       +MOD_AT+   
         |              |       |         |              |        |       |       |     |             |        |      |   |           |            |           |       |      |   
 In lymphocytes from __SP__ , oral administration of __NODE__ ( with a dosage of 600 mg/day and a treatment period of 7 days ) is involved in expression of __SP__ __NODE__ mRNA .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
APPOS (administration,period)
OBJ:V-N (with,mg/day)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,day)
MOD_ATT:N-ADJ (day,7)
COMP:V_PASS-N(In) (involve,lymphocyte)
COMP:V_PASS-N(from) (involve,__SP__)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
Analyse 8 
         +------------------------------------------------------COMP:V_PASS-N(In)-----------------------------------------------------+                                           
         |                                +---------------------------------------SUBJ:V_PASS-N---------------------------------------+                                           
         |                                |                       +-------------------OBJ:V-N------------------+                      |                                           
         |                                |                       |                     +-----------COMP:N-N(of)----------+           |            +-------COMP:N-N(of)-------+   
         |                                |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+           |            |           +-MOD_ATT:N-ADJ+   
         +COMP:N-N(from)+       +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+           +COMP:V_PASS-+           |       +MOD_AT+   
         |              |       |         |              |        |       |       |     |             |        |      |   |           |            |           |       |      |   
 In lymphocytes from __SP__ , oral administration of __NODE__ ( with a dosage of 600 mg/day and a treatment period of 7 days ) is involved in expression of __SP__ __NODE__ mRNA .
COMP:N-N(from) (lymphocyte,__SP__)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,day)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,day)
MOD_ATT:N-ADJ (day,7)
COMP:V_PASS-N(In) (involve,lymphocyte)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
Analyse 9 
         +------------------------------------------------------COMP:V_PASS-N(In)-----------------------------------------------------+                                           
         |                                +---------------------------------------SUBJ:V_PASS-N---------------------------------------+                                           
         |                                |                       +-------------------OBJ:V-N------------------+                      |                                           
         |                                |                       |                     +-----------COMP:N-N(of)----------+           |            +-------COMP:N-N(of)-------+   
         |                                |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+           |            |           +-MOD_ATT:N-ADJ+   
         +COMP:N-N(from)+       +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+           +COMP:V_PASS-+           |       +MOD_AT+   
         |              |       |         |              |        |       |       |     |             |        |      |   |           |            |           |       |      |   
 In lymphocytes from __SP__ , oral administration of __NODE__ ( with a dosage of 600 mg/day and a treatment period of 7 days ) is involved in expression of __SP__ __NODE__ mRNA .
COMP:N-N(from) (lymphocyte,__SP__)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,day)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,day)
MOD_ATT:N-ADJ (day,7)
COMP:V_PASS-N(In) (involve,lymphocyte)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
Analyse 10 
         +------------------------------------------------------COMP:V_PASS-N(In)-----------------------------------------------------+                                           
         |              +---------------------------------------------COMP:V_PASS-N(from)---------------------------------------------+                                           
         |              |                 +---------------------------------------SUBJ:V_PASS-N---------------------------------------+                                           
         |              |                 |                       +-------------------OBJ:V-N------------------+                      |                                           
         |              |                 |                       |                     +-----------COMP:N-N(of)----------+           |            +-------COMP:N-N(of)-------+   
         |              |                 |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+           |            |           +-MOD_ATT:N-ADJ+   
         |              |       +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+           +COMP:V_PASS-+           |       +MOD_AT+   
         |              |       |         |              |        |       |       |     |             |        |      |   |           |            |           |       |      |   
 In lymphocytes from __SP__ , oral administration of __NODE__ ( with a dosage of 600 mg/day and a treatment period of 7 days ) is involved in expression of __SP__ __NODE__ mRNA .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,day)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,day)
MOD_ATT:N-ADJ (day,7)
COMP:V_PASS-N(In) (involve,lymphocyte)
COMP:V_PASS-N(from) (involve,__SP__)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
Analyse 11 
         +------------------------------------------------------COMP:V_PASS-N(In)-----------------------------------------------------+                                           
         |              +---------------------------------------------COMP:V_PASS-N(from)---------------------------------------------+                                           
         |              |                 +---------------------------------------SUBJ:V_PASS-N---------------------------------------+                                           
         |              |                 |                       +-------------------OBJ:V-N------------------+                      |                                           
         |              |                 |                       |                     +-----------COMP:N-N(of)----------+           |            +-------COMP:N-N(of)-------+   
         |              |                 |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+           |            |           +-MOD_ATT:N-ADJ+   
         |              |       +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+           +COMP:V_PASS-+           |       +MOD_AT+   
         |              |       |         |              |        |       |       |     |             |        |      |   |           |            |           |       |      |   
 In lymphocytes from __SP__ , oral administration of __NODE__ ( with a dosage of 600 mg/day and a treatment period of 7 days ) is involved in expression of __SP__ __NODE__ mRNA .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,day)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,day)
MOD_ATT:N-ADJ (day,7)
COMP:V_PASS-N(In) (involve,lymphocyte)
COMP:V_PASS-N(from) (involve,__SP__)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
Analyse 12 
         +------------------------------------------------------COMP:V_PASS-N(In)-----------------------------------------------------+                                           
         |                                +---------------------------------------SUBJ:V_PASS-N---------------------------------------+                                           
         |                                |                       +-------------------OBJ:V-N------------------+                      |                                           
         |                                |                       |                     +-----------COMP:N-N(of)----------+           |            +-------COMP:N-N(of)-------+   
         |                                |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+           |            |           +-MOD_ATT:N-ADJ+   
         +COMP:N-N(from)+       +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+           +COMP:V_PASS-+           |       +MOD_AT+   
         |              |       |         |              |        |       |       |     |             |        |      |   |           |            |           |       |      |   
 In lymphocytes from __SP__ , oral administration of __NODE__ ( with a dosage of 600 mg/day and a treatment period of 7 days ) is involved in expression of __SP__ __NODE__ mRNA .
COMP:N-N(from) (lymphocyte,__SP__)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,day)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,day)
MOD_ATT:N-ADJ (day,7)
COMP:V_PASS-N(In) (involve,lymphocyte)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
Analyse 13 
         +------------------------------------------------------COMP:V_PASS-N(In)-----------------------------------------------------+                                           
         |                                +---------------------------------------SUBJ:V_PASS-N---------------------------------------+                                           
         |                                |                       +-------------------OBJ:V-N------------------+                      |                                           
         |                                |                       |                     +-----------COMP:N-N(of)----------+           |            +-------COMP:N-N(of)-------+   
         |                                |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+           |            |           +-MOD_ATT:N-ADJ+   
         +COMP:N-N(from)+       +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+           +COMP:V_PASS-+           |       +MOD_AT+   
         |              |       |         |              |        |       |       |     |             |        |      |   |           |            |           |       |      |   
 In lymphocytes from __SP__ , oral administration of __NODE__ ( with a dosage of 600 mg/day and a treatment period of 7 days ) is involved in expression of __SP__ __NODE__ mRNA .
COMP:N-N(from) (lymphocyte,__SP__)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,day)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,day)
MOD_ATT:N-ADJ (day,7)
COMP:V_PASS-N(In) (involve,lymphocyte)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
Analyse 14 
         +------------------------------------------------------COMP:V_PASS-N(In)-----------------------------------------------------+                                           
         |              +---------------------------------------------COMP:V_PASS-N(from)---------------------------------------------+                                           
         |              |                 +---------------------------------------SUBJ:V_PASS-N---------------------------------------+                                           
         |              |                 |                       +-------------------OBJ:V-N------------------+                      |                                           
         |              |                 |                       |                     +-----------COMP:N-N(of)----------+           |            +-------COMP:N-N(of)-------+   
         |              |                 |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+           |            |           +-MOD_ATT:N-ADJ+   
         |              |       +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+           +COMP:V_PASS-+           |       +MOD_AT+   
         |              |       |         |              |        |       |       |     |             |        |      |   |           |            |           |       |      |   
 In lymphocytes from __SP__ , oral administration of __NODE__ ( with a dosage of 600 mg/day and a treatment period of 7 days ) is involved in expression of __SP__ __NODE__ mRNA .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,day)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,day)
MOD_ATT:N-ADJ (day,7)
COMP:V_PASS-N(In) (involve,lymphocyte)
COMP:V_PASS-N(from) (involve,__SP__)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
Analyse 15 
         +------------------------------------------------------COMP:V_PASS-N(In)-----------------------------------------------------+                                           
         |              +---------------------------------------------COMP:V_PASS-N(from)---------------------------------------------+                                           
         |              |                 +---------------------------------------SUBJ:V_PASS-N---------------------------------------+                                           
         |              |                 |                       +-------------------OBJ:V-N------------------+                      |                                           
         |              |                 |                       |                     +-----------COMP:N-N(of)----------+           |            +-------COMP:N-N(of)-------+   
         |              |                 |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+           |            |           +-MOD_ATT:N-ADJ+   
         |              |       +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+           +COMP:V_PASS-+           |       +MOD_AT+   
         |              |       |         |              |        |       |       |     |             |        |      |   |           |            |           |       |      |   
 In lymphocytes from __SP__ , oral administration of __NODE__ ( with a dosage of 600 mg/day and a treatment period of 7 days ) is involved in expression of __SP__ __NODE__ mRNA .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
COMP:N-N(of) (mg/day,day)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,day)
MOD_ATT:N-ADJ (day,7)
COMP:V_PASS-N(In) (involve,lymphocyte)
COMP:V_PASS-N(from) (involve,__SP__)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
Analyse 16 
         +------------------------------------------------------COMP:V_PASS-N(In)-----------------------------------------------------+                                           
         |                                +---------------------------------------SUBJ:V_PASS-N---------------------------------------+                                           
         |                                |                       +-------------------OBJ:V-N------------------+                      |            +-------COMP:N-N(of)-------+   
         |                                |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+           |            |           +-MOD_ATT:N-ADJ+   
         +COMP:N-N(from)+       +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+           +COMP:V_PASS-+           |       +MOD_AT+   
         |              |       |         |              |        |       |       |     |             |        |      |   |           |            |           |       |      |   
 In lymphocytes from __SP__ , oral administration of __NODE__ ( with a dosage of 600 mg/day and a treatment period of 7 days ) is involved in expression of __SP__ __NODE__ mRNA .
COMP:N-N(from) (lymphocyte,__SP__)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,day)
MOD_ATT:N-ADJ (day,7)
COMP:V_PASS-N(In) (involve,lymphocyte)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
Analyse 17 
         +------------------------------------------------------COMP:V_PASS-N(In)-----------------------------------------------------+                                           
         |                                +---------------------------------------SUBJ:V_PASS-N---------------------------------------+                                           
         |                                |                       +-------------------OBJ:V-N------------------+                      |            +-------COMP:N-N(of)-------+   
         |                                |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+           |            |           +-MOD_ATT:N-ADJ+   
         +COMP:N-N(from)+       +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+           +COMP:V_PASS-+           |       +MOD_AT+   
         |              |       |         |              |        |       |       |     |             |        |      |   |           |            |           |       |      |   
 In lymphocytes from __SP__ , oral administration of __NODE__ ( with a dosage of 600 mg/day and a treatment period of 7 days ) is involved in expression of __SP__ __NODE__ mRNA .
COMP:N-N(from) (lymphocyte,__SP__)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,day)
MOD_ATT:N-ADJ (day,7)
COMP:V_PASS-N(In) (involve,lymphocyte)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
Analyse 18 
         +------------------------------------------------------COMP:V_PASS-N(In)-----------------------------------------------------+                                           
         |              +---------------------------------------------COMP:V_PASS-N(from)---------------------------------------------+                                           
         |              |                 +---------------------------------------SUBJ:V_PASS-N---------------------------------------+                                           
         |              |                 |                       +-------------------OBJ:V-N------------------+                      |            +-------COMP:N-N(of)-------+   
         |              |                 |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+           |            |           +-MOD_ATT:N-ADJ+   
         |              |       +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+           +COMP:V_PASS-+           |       +MOD_AT+   
         |              |       |         |              |        |       |       |     |             |        |      |   |           |            |           |       |      |   
 In lymphocytes from __SP__ , oral administration of __NODE__ ( with a dosage of 600 mg/day and a treatment period of 7 days ) is involved in expression of __SP__ __NODE__ mRNA .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,day)
MOD_ATT:N-ADJ (day,7)
COMP:V_PASS-N(In) (involve,lymphocyte)
COMP:V_PASS-N(from) (involve,__SP__)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
Analyse 19 
         +------------------------------------------------------COMP:V_PASS-N(In)-----------------------------------------------------+                                           
         |              +---------------------------------------------COMP:V_PASS-N(from)---------------------------------------------+                                           
         |              |                 +---------------------------------------SUBJ:V_PASS-N---------------------------------------+                                           
         |              |                 |                       +-------------------OBJ:V-N------------------+                      |            +-------COMP:N-N(of)-------+   
         |              |                 |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+           |            |           +-MOD_ATT:N-ADJ+   
         |              |       +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+           +COMP:V_PASS-+           |       +MOD_AT+   
         |              |       |         |              |        |       |       |     |             |        |      |   |           |            |           |       |      |   
 In lymphocytes from __SP__ , oral administration of __NODE__ ( with a dosage of 600 mg/day and a treatment period of 7 days ) is involved in expression of __SP__ __NODE__ mRNA .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,day)
MOD_ATT:N-ADJ (day,7)
COMP:V_PASS-N(In) (involve,lymphocyte)
COMP:V_PASS-N(from) (involve,__SP__)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
Analyse 20 
         +------------------------------------------------------COMP:V_PASS-N(In)-----------------------------------------------------+                                           
         |                                +---------------------------------------SUBJ:V_PASS-N---------------------------------------+                                           
         |                                |                       +-------------------OBJ:V-N------------------+                      |            +-------COMP:N-N(of)-------+   
         |                                |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+           |            |           +-MOD_ATT:N-ADJ+   
         +COMP:N-N(from)+       +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+           +COMP:V_PASS-+           |       +MOD_AT+   
         |              |       |         |              |        |       |       |     |             |        |      |   |           |            |           |       |      |   
 In lymphocytes from __SP__ , oral administration of __NODE__ ( with a dosage of 600 mg/day and a treatment period of 7 days ) is involved in expression of __SP__ __NODE__ mRNA .
COMP:N-N(from) (lymphocyte,__SP__)
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,day)
MOD_ATT:N-ADJ (day,7)
COMP:V_PASS-N(In) (involve,lymphocyte)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
Analyse 21 
         +------------------------------------------------------COMP:V_PASS-N(In)-----------------------------------------------------+                                           
         |                                +---------------------------------------SUBJ:V_PASS-N---------------------------------------+                                           
         |                                |                       +-------------------OBJ:V-N------------------+                      |            +-------COMP:N-N(of)-------+   
         |                                |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+           |            |           +-MOD_ATT:N-ADJ+   
         +COMP:N-N(from)+       +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+           +COMP:V_PASS-+           |       +MOD_AT+   
         |              |       |         |              |        |       |       |     |             |        |      |   |           |            |           |       |      |   
 In lymphocytes from __SP__ , oral administration of __NODE__ ( with a dosage of 600 mg/day and a treatment period of 7 days ) is involved in expression of __SP__ __NODE__ mRNA .
COMP:N-N(from) (lymphocyte,__SP__)
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,day)
MOD_ATT:N-ADJ (day,7)
COMP:V_PASS-N(In) (involve,lymphocyte)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
Analyse 22 
         +------------------------------------------------------COMP:V_PASS-N(In)-----------------------------------------------------+                                           
         |              +---------------------------------------------COMP:V_PASS-N(from)---------------------------------------------+                                           
         |              |                 +---------------------------------------SUBJ:V_PASS-N---------------------------------------+                                           
         |              |                 |                       +-------------------OBJ:V-N------------------+                      |            +-------COMP:N-N(of)-------+   
         |              |                 |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+           |            |           +-MOD_ATT:N-ADJ+   
         |              |       +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+           +COMP:V_PASS-+           |       +MOD_AT+   
         |              |       |         |              |        |       |       |     |             |        |      |   |           |            |           |       |      |   
 In lymphocytes from __SP__ , oral administration of __NODE__ ( with a dosage of 600 mg/day and a treatment period of 7 days ) is involved in expression of __SP__ __NODE__ mRNA .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,day)
MOD_ATT:N-ADJ (day,7)
COMP:V_PASS-N(In) (involve,lymphocyte)
COMP:V_PASS-N(from) (involve,__SP__)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
Analyse 23 
         +------------------------------------------------------COMP:V_PASS-N(In)-----------------------------------------------------+                                           
         |              +---------------------------------------------COMP:V_PASS-N(from)---------------------------------------------+                                           
         |              |                 +---------------------------------------SUBJ:V_PASS-N---------------------------------------+                                           
         |              |                 |                       +-------------------OBJ:V-N------------------+                      |            +-------COMP:N-N(of)-------+   
         |              |                 |                       +-------OBJ:V-N-------+                      +COMP:N-N(o+           |            |           +-MOD_ATT:N-ADJ+   
         |              |       +MOD_ATT:N+-COMP:N-N(of)-+        |       +COMP:N-+     |             +MOD_ATT:+      +MOD+           +COMP:V_PASS-+           |       +MOD_AT+   
         |              |       |         |              |        |       |       |     |             |        |      |   |           |            |           |       |      |   
 In lymphocytes from __SP__ , oral administration of __NODE__ ( with a dosage of 600 mg/day and a treatment period of 7 days ) is involved in expression of __SP__ __NODE__ mRNA .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,mg/day)
OBJ:V-N (with,period)
COMP:N-N(of) (dosage,@card@)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,day)
MOD_ATT:N-ADJ (day,7)
COMP:V_PASS-N(In) (involve,lymphocyte)
COMP:V_PASS-N(from) (involve,__SP__)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)